动态动脉弹性对停用血管升压药的预测价值:系统评价与荟萃分析
该系统评价与荟萃分析按PRISMA清单进行、方案于2023年5月26日在PROSPERO注册(CRD42023421462),纳入MEDLINE与Embase截至2023年5月的前瞻性观察研究。定量分析共5项研究、183例患者,76%为脓毒症休克,平均压力反应率为36.20%。Eadyn预测停用血管升压药后低血压的汇总AUC为0.85,灵敏度0.87(95%CI 0.74-0.93)、特异度0.76(95%CI 0.68-0.83)、诊断比值比19.07(95%CI 8.47-42.92);亚组分析显示去甲肾上腺素剂量、Eadyn测量设备及Eadyn诊断界值均不影响预测表现。作者结论认为Eadyn对危重患者停用血管升压药支持具有良好预测能力。
要点
- 5项前瞻性观察研究、183例ICU危重成人中,Eadyn预测停用血管升压药后低血压的汇总AUC为0.85。
- 汇总灵敏度0.87(95%CI 0.74-0.93)、特异度0.76(95%CI 0.68-0.83)、诊断比值比19.07(95%CI 8.47-42.92)。
- 纳入患者76%为脓毒症休克,其余因其他原因使用去甲肾上腺素,平均压力反应率36.20%。
- 亚组分析显示去甲肾上腺素剂量、Eadyn测量设备及诊断界值均未使Eadyn预测停用血管升压药的表现出现差异。
- 作者结论认为Eadyn对危重患者停用血管升压药支持具有良好预测能力。
适用人群与场景
- 入住重症监护室的危重成人患者,无论诊断为何;纳入的多数患者(76%)诊断为脓毒症休克,其余患者因其他原因需要去甲肾上腺素。
研究设计与关键结果
- 研究类型为系统评价与荟萃分析,按PRISMA清单进行,方案于2023年5月26日在PROSPERO注册(CRD42023421462)。
- 纳入MEDLINE与Embase数据库截至2023年5月的前瞻性观察研究,定量分析共5项研究、183例患者。
- 提取数据包括患者临床特征、Eadyn测量方法、结果及去甲肾上腺素剂量;平均压力反应率为36.20%。
- Eadyn预测停用血管升压药后低血压的汇总AUC为0.85,灵敏度0.87(95%CI 0.74-0.93),特异度0.76(95%CI 0.68-0.83),诊断比值比19.07(95%CI 8.47-42.92)。
- 亚组分析显示,去甲肾上腺素剂量、Eadyn测量设备及Eadyn诊断界值均未使Eadyn预测停用血管升压药支持的表现出现差异。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,经亚组分析评估,Eadyn对危重患者停用血管升压药支持具有良好预测能力。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Dynamic arterial elastance (Eadyn) has been investigated for its ability to predict hypotension during the weaning of vasopressors. Our study focused on assessing Eadyn's performance in the context of critically ill adult patients admitted to the intensive care unit, regardless of diagnosis.
MAIN BODY: Our study was conducted in accordance with the Preferred Reported Items for Systematic Reviews and Meta-Analysis checklist. The protocol was registered in PROSPERO (CRD42023421462) on May 26, 2023. We included prospective observational studies from the MEDLINE and Embase databases through May 2023. Five studies involving 183 patients were included in the quantitative analysis. We extracted data related to patient clinical characteristics, and information about Eadyn measurement methods, results, and norepinephrine dose. Most patients (76%) were diagnosed with septic shock, while the remaining patients required norepinephrine for other reasons. The average pressure responsiveness rate was 36.20%. The synthesized results yielded an area under the curve of 0.85, with a sensitivity of 0.87 (95% CI 0.74-0.93), specificity of 0.76 (95% CI 0.68-0.83), and diagnostic odds ratio of 19.07 (95% CI 8.47-42.92). Subgroup analyses indicated no variations in the Eadyn based on norepinephrine dosage, the Eadyn measurement device, or the Eadyn diagnostic cutoff to predict cessation of vasopressor support.
CONCLUSIONS: Eadyn, evaluated through subgroup analyses, demonstrated good predictive ability for the discontinuation of vasopressor support in critically ill patients.
参考来源
- Alvarado-Sánchez JI, Salazar-Ruiz S, Caicedo-Ruiz JD, et al. Predictive value of dynamic arterial elastance for vasopressor withdrawal: a systematic review and meta-analysis. Ann Intensive Care. 2024. PMID: 38980442. doi:10.1186/s13613-024-01345-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。